Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Opko Health Inc. (OPK), PROLOR Biotech Inc (PBTH): This Acquisition Offers a Major Arbitrage Opportunity, But Conditions Apply

Page 1 of 2

In late April, biotechnology firm Opko Health Inc. (NYSE:OPK) announced that it would acquire Israeli pharmaceutical start-up PROLOR Biotech Inc (NYSEMKT:PBTH) in a stock-for-stock deal that currently offers a substantial arbitrage premium. Investors have every right to be interested in this deal. In addition to some exciting operational synergies, it offers one of the clearest merger arbitrage opportunities seen in the past 12 months.

Opko Health Inc. (NYSE:OPK)However, this proposed merger is not without its risks. For starters, the arbitrage trade is threatened by the vagaries of Opko’s volatile stock price. Perhaps, more importantly, the deal itself faces a slew of threatened legal actions in the U.S. and Israel. In addition, Opko’s chairman is dealing with serious conflict-of-interest allegations that stem from his interest in both companies. Before assessing whether these hurdles will impede the ultimate completion of this deal, it would be wise to compare Opko and PROLOR in greater detail.

A closer look at PROLOR and Opko

PROLOR and Opko Health Inc. (NYSE:OPKhave many functional differences. Among other things, PROLOR is styled as a start-up and lacks a market-ready product. Although some of its compounds are well on their way to FDA approval, it should not be mistaken for an established biotechnology or pharmaceutical firm. In contrast, Opko’s development pipeline is more mature and provides its balance sheet with at least some revenue.

PROLOR remains a much smaller firm than Opko. Its market capitalization of just over $410 million is paltry relative to Opko’s $2.4 billion. In 2012, the company had no substantial revenue and suffered an after-tax loss of nearly $20 million due to development and payroll expenses. In contrast, Opko took in around $70 million and posted a loss of about $57 million.

PROLOR Biotech Inc (NYSEMKT:PBTH) retains about $30 million of its initial cash funding and holds no debt on its books. Opko Health Inc. (NYSE:OPK) has a manageable debt load of $220 million, and an adequate but shrinking cash reserve of $180 million. Unfortunately, PROLOR’s minus $15 million cash flow figure hints that the company will soon require additional funding in the event the proposed merger falls through.

How the deal is structured

This merger is structured as a fairly traditional stock-for-stock deal. Under the terms of the proposal, Opko will provide current PROLOR shareholders with .9951 share of Opko Health Inc. (NYSE:OPK) for every PROLOR share that they hold. At Opko’s current stock price of about $7.10 per share, this values each PROLOR share at roughly $7.06. Relative to PROLOR’s current price of around $6.53 per share, this makes for an arbitrage premium of about 8.1%. The entire transaction is valued at just under $500 million. If the various complications in play do not derail or delay it, it should close by the end of 2013.

Page 1 of 2